Filing Flows › Northwest Biotherapeutics (NWBO) › Q2 2026 › vs Q2 2025
Northwest Biotherapeutics (NWBO) Q2 2026 vs Q2 2025 (year over year)
Northwest Biotherapeutics's revenue rose $676K (+516%) from $131K in Q2 2025 to $807K in Q2 2026.
Northwest Biotherapeutics, Q2 2026: revenue $807K (+516% year over year), net loss $15.4M, operating cash flow −$7.2M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $807K | $131K | $676K | +516% |
| Net loss | $15.4M | $15.4M | $0 | 0% |
| Costs & expenses | $16.2M | $15.5M | $676K | +4% |
| Operating costs | $12.4M | $14.9M | −$2.5M | -17% |
| Interest & other, net | $3.8M | $621K | $3.2M | +511% |
| Research & development | $5.7M | $7.4M | −$1.7M | -23% |
| General & admin | $6.7M | $7.5M | −$773K | -10% |
| Operating cash sources | $15.4M | $15.4M | $0 | 0% |
| Depreciation & amortization | $774K | $500K | $274K | +55% |
| Share-based compensation | $181K | $364K | −$183K | -50% |
| Working capital & other | $7.3M | $7.8M | −$572K | -7% |
| Cash used in operations | $7.2M | $6.7M | $481K | +7% |
| Net loss absorbed | $15.4M | $15.4M | $0 | 0% |
Questions
How much did Northwest Biotherapeutics's revenue grow year over year in Q2 2026?
Northwest Biotherapeutics's revenue rose $676K (+516%) from $131K in Q2 2025 to $807K in Q2 2026.